Phase 3 AMPLITUDE Trial Supports FDA Approval of Akeega in mCSPC
FDA approves Akeega (niraparib + abiraterone acetate with prednisone) for BRCA2-mutated metastatic castration-sensitive prostate cancer, showing significant improvements in radiographic progression-free survival and delayed symptomatic...
